235: A Treatment For Adults With Active Psoriatic Arthritis Or Moderate To Severe Plaque Psoriasis

Industry Presenter(s)

• 

  John Tesser, MD, FACP, FACR

  Adjunct Assistant Professor
  Arizona Arthritis & Rheumatology Associates
  Phoenix, AZ, United States

  Disclosure information not submitted.
• SD

  Sheetal Desai, MD, MSEd

  Chief of Rheumatology, Director, Lupus Clinic
  University of California, Irvine
  Irvine, California, United States

  Disclosure information not submitted.
• GL

  Gordon Lam, MD

  Medical Director, Clinical Research
  Arthritis and Osteoporosis Consultants of the Carolinas
  Cornelius, NC, United States

  Disclosure information not submitted.

This session will review of the safety and efficacy of a biologic targeting IL-23 in patients with Active Psoriatic Arthritis and Moderate to severe plaque psoriasis who are candidates for systemic therapy or photo therapy.

Topics Include:

• Mechanism of Action of and IL-23 Inhibitor
• Current Dosing and Indications
• A Review of phase 3 clinical trial results, including week 12 data from Discover 2 and week 60 data from Discover 1
• A Review of additional endpoints, including IGA0/1, FACIT-Fatigue, BASDAI, and MDA
• A Review of the safety profile of TREMFYA in psoriatic arthritis
• 
  A Review of head-tohead data from the Eclipse Trial
• Review Important Safety Information for use in Psoriatic Arthritis and Plaque Psoriasis.

Developed & offered by Janssen Pharmaceuticals, Inc.